Incidence of invasive fungal infections in patients with chronic lymphocytic leukemia receiving ibrutinib within the veteran's healthcare administration.

Cassandra Walker Amy MorrowZohra NooruddinChristopher R Frei

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2023)

The reported IFI incidence of 1.3% is comparable to current estimates of 1.2%. Future studies should examine the relationship of ibrutinib and incidence of IFIs in first-line and R/R settings in addition to identifying clinical risk factors predisposing patients to IFIs.

Keyphrases

chronic lymphocytic leukemia
risk factors
healthcare
end stage renal disease
chronic kidney disease
newly diagnosed
ejection fraction
prognostic factors
current status
patient reported
cell wall